Lyell Immunopharma
Lyell Immunopharma Inc is an American clinical-stage cell therapy biopharmaceutical company developing reprogrammed T-cell therapies for solid tumors. The company utilizes its proprietary Gen-R and Epi-R technology platforms to overcome T-cell exhaustion and enhance functional durability in CAR-T and TIL cellular immunotherapies. Principal revenue is driven through research milestone payments, strategic development partnerships, and capital raises ahead of commercial market authorization. Core end markets encompass medical oncology clinics, clinical trial hospital centers, and solid tumor prescription patients globally. Lyell Immunopharma holds an innovative position in the biopharmaceutical sector as a developer of next-generation cell therapies targeting solid organ cancers. The corporation is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Lyell Immunopharma.
- Legal name
- Lyell Immunopharma Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Lyell Immunopharma
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)